Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDMTR.L Regulatory News (DMTR)

  • There is currently no data for DMTR

Project Announcement

3 Feb 2014 07:00

RNS Number : 0540Z
Oxford Advanced Surfaces Group PLC
03 February 2014
 



OXFORD ADVANCED SURFACES GROUP PLC

(AIM: OXA)

 

OAS enters into TSB funded project with Sun Chemical Limited

 

Oxford Advanced Surfaces Group ("OAS"), the AIM listed technology developer targeting engineered materials and surface modification applications in the automotive, aerospace, communications and renewable energy markets is pleased to announce that it is working in partnership with Sun Chemical Limited ("Sun") on OntoTM cross-linker based formulations for radiation curable ("radcure") coatings supported by a total grant of £179,000 from the UK's innovation agency, the Technology Strategy Board.

 

The radcure coatings market is an area of significant growth and continues to gain popularity due to the fast cure times and environmentally friendly credentials the products offer.

 

The project aims to create a novel radcure coating platform that can bring differentiation to ink-jet printable inks for the graphic signage and packaging market areas. Combining Sun's sustainable materials in conjunction with OAS's proprietary OntoTM chemistry, we plan to develop ink formulations that bond to surfaces without pre-treatments using low power radiation sources for curing. The elimination of harmful solvents in these formulations combined with the improved processing conditions will all contribute to products with lower environmental impact.

 

Success in the inkjet market will lead to further exploitation in the graphic arts market and more broadly in other UV-curable coating markets.

 

Philip Spinks, CEO, commented:

 

"We are delighted to be working with a market leader like Sun addressing both adhesion and environmental issues in broad manufacturing applications. The 30 month development programme will commence at the start of February with funding support from the Technology Strategy Board."

 

3 February 2014

 

Enquiries:

 

Oxford Advances Surfaces Group Plc

www.oxfordsurfaces.com

 

Philip Spinks, Chief Executive Officer T: 01865 854 807

 

W H Ireland Limited

www.wh-ireland.co.uk

 

John Wakefield T: 0117 945 3471

 

 

Editors' Note

Oxford Advanced Surfaces Group (OAS) is the AIM listed technology developer targeting engineered materials and surface modification applications in multiple markets including automotive, aerospace, communications and renewable energy. Our proprietary Onto™ highly reactive chemistry provides manufacturers with versatile technology solutions in surface functionalisation and adhesion promotion of coatings, inks and adhesives to difficult-to-bond substrates. Onto™ can be integrated into customer manufacturing lines for use in a wide range of surface modification applications for high-performance plastics, low surface energy polymers and composites.

Onto™ technology creates permanent bonding to surfaces through the use of highly reactive carbene chemistry. Carbenes can react with almost anything, even difficult-to-bond materials with limited or no functionality such as polyethylene, making Onto™ a diverse surface modification technology for a wide range of materials. Onto™ is processed from solution using typical wet process techniques and can be integrated into custom manufacturing facilities. The chemistry is flexible and can be manipulated to provide a variety of properties to a surface, giving it scope for use in a broad range of applications and markets.

The Technology Strategy Board is the UK's innovation agency. Its goal is to accelerate economic growth by stimulating and supporting business-led innovation. Sponsored by the Department for Business, Innovation and Skills (BIS), the Technology Strategy Board brings together business, research and the public sector, supporting and accelerating the development of innovative products and services to meet market needs, tackle major societal challenges and help build the future economy. For more information please visit www.innovateuk.org.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAKFFDLKLEFF
Date   Source Headline
24th Jan 20228:50 amRNSHolding(s) in Company
24th Jan 20227:00 amRNSHolding(s) in Company
20th Jan 202212:15 pmRNSResult of General Meeting
20th Jan 20227:00 amRNSResult of Open Offer - Correction
19th Jan 202211:30 amRNSResult of Open Offer
4th Jan 20221:30 pmRNSPosting of Circular and Notice of GM
29th Dec 20214:36 pmRNSPrice Monitoring Extension
24th Dec 20217:00 amRNSPlacing, Subscription and Open Offer
17th Dec 20215:00 pmRNSBusiness Update and Financing
22nd Oct 20217:00 amRNSAppointment of new Scientific Advisory Board
21st Oct 20218:00 amRNSDigitalGlassware® platform trial with Aurigene
28th Sep 20217:00 amRNSCollaboration
22nd Sep 20217:00 amRNSHalf Year Results
14th Sep 202110:30 amRNSNotice of Half Year Results
8th Sep 20211:30 pmRNSHolding(s) in Company
18th Aug 20217:00 amRNSAdvisory Board Appointment
5th Aug 20217:00 amRNSCollaboration with the University of Cambridge
12th Jul 20217:00 amRNSAppointment of Non-Executive Director
30th Jun 20213:34 pmRNSResult of AGM
22nd Jun 20217:00 amRNSChanges to 2021 AGM Arrangements
17th Jun 20217:00 amRNSCollaboration with the University of Leeds
8th Jun 20213:16 pmRNSPosting of ARA and Updated Notice of AGM
1st Jun 20217:00 amRNSFinal Results
24th May 20217:00 amRNSNotice of Results and Investor Presentation
6th May 20213:43 pmRNSHolding(s) in Company
7th Apr 20217:00 amRNSCollaboration with the University of Nottingham
11th Mar 20217:00 amRNSCo-distribution agreement with Elemental Machines
9th Mar 20217:00 amRNSDirectorate Change
20th Jan 20217:00 amRNSAgreement with Merck's Life Sciences business
19th Jan 20217:00 amRNSHolding(s) in Company
8th Jan 20212:00 pmRNSPrice Monitoring Extension
18th Dec 202010:30 amRNSGrant of PDMR Options
17th Dec 20207:00 amRNSMulti-year contract with Thieme Chemistry
26th Oct 202011:05 amRNSSecond Price Monitoring Extn
26th Oct 202011:00 amRNSPrice Monitoring Extension
21st Oct 20207:00 amRNSIssue of Shares and Total Voting Rights
19th Oct 20207:00 amRNSDirectorate Changes
16th Oct 20207:00 amRNSStrong adoption of ICSYNTH
2nd Oct 20202:05 pmRNSSecond Price Monitoring Extn
2nd Oct 20202:00 pmRNSPrice Monitoring Extension
1st Oct 20208:00 amRNSGrant of Options
29th Sep 20207:00 amRNSHolding(s) in Company
23rd Sep 20201:40 pmRNSHolding(s) in Company
22nd Sep 20204:29 pmRNSHolding(s) in Company
22nd Sep 20204:00 pmRNSHolding(s) in Company
22nd Sep 202010:32 amRNSHolding(s) in Company
15th Sep 20208:08 amRNSIssue of Shares and Total Voting Rights
10th Sep 20207:00 amRNSHalf-year Report
4th Sep 20208:26 amRNSHolding(s) in Company
3rd Sep 20207:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.